We analyze peer-reviewed research on supplements.
We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Podcast
Download PDF Protocol
Download ProtocolPriming Dogs’ Immune Systems with β-Glucan May Improve Rabies Vaccine ProtectionNew
Yeast-Derived Particles Prove Safe and Highly Effective Immune Boosters for Next-Generation VaccinesNew
A Two-Dose Respiratory syncytial virus (RSV) Vaccine Incorporating Beta-glucan (β-glucan) as a Vaccine adjuvant is Safe for Older AdultsNew
- Itoh Immunopharmacological study of sulfated schizophyllan (SPG). I. Its action as a mitogen and anti-HIV agent. 1990
- Hotta Augmentation of protective immune responses against Sendai virus infection by fungal polysaccharide schizophyllan 1993
- Guo Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine 2009
- Harnack Oral administration of a soluble 1-3, 1-6 β-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice. 2009
- Paris β-Glucan as Trained Immunity-Based Adjuvants for Rabies Vaccines in Dogs 2020
- Ikewaki β-glucans: wide-spectrum immune-balancing food-supplement-based enteric (β-WIFE) vaccine adjuvant approach to COVID-19. 2021
- Ikewaki β-glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B-VACCIEN) in specific immunocompromised populations (Review) 2022
- Panão-Costa Yeast-Derived Glucan Particles: Biocompatibility, Efficacy, and Immunomodulatory Potential as Adjuvants and Delivery Systems 2025
- Nakayama Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study 2025